Compare ATMU & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | CRSP |
|---|---|---|
| Founded | 1958 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 5.1B |
| IPO Year | 2023 | 2016 |
| Metric | ATMU | CRSP |
|---|---|---|
| Price | $55.43 | $56.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 19 |
| Target Price | $49.50 | ★ $71.50 |
| AVG Volume (30 Days) | 569.3K | ★ 1.7M |
| Earning Date | 02-20-2026 | 02-10-2026 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | ★ 11.13 | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $1,724,400,000.00 | $38,337,000.00 |
| Revenue This Year | $6.37 | N/A |
| Revenue Next Year | $4.11 | $718.51 |
| P/E Ratio | $23.08 | ★ N/A |
| Revenue Growth | ★ 3.72 | N/A |
| 52 Week Low | $30.94 | $30.04 |
| 52 Week High | $55.78 | $78.48 |
| Indicator | ATMU | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 65.80 | 51.43 |
| Support Level | $51.76 | $53.37 |
| Resistance Level | $55.13 | $60.73 |
| Average True Range (ATR) | 1.21 | 2.33 |
| MACD | 0.09 | 0.12 |
| Stochastic Oscillator | 94.04 | 47.39 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. The company designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.